NONOF
Novo Nordisk A/S
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Strong sell
-65/100
Last price
37.39
▲ 0.05 (0.13%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
37.34
Day high
37.15
Day low
36.90
Volume
400
Market cap
$165.05B
P/E (TTM)
9.14
52W range
34.00 – 64.75
Trailing performance
Returnvs SPY
1W
-2.48%
-4.4%
1M
-19.26%
-20.4%
3M
-22.31%
-26.8%
6M
+4.09%
-14.1%
YTD
-26.76%
-41.0%
1Y
-37.45%
-53.9%
3Y
-58.95%
-141.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on NONOF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
233.45M
Total on file
Fundamentals
Market cap$165.05B
Enterprise value$260.73B
Revenue (TTM)$329.43B
Gross profit$270.09B
EBITDA$173.68B
Net income$116.44B
EPS (TTM)$4.09
Free cash flow$37.67B
Total cash$44.98B
Total debt$140.13B
Book value / share$7.58
Shares outstanding3.34B
Float3.17B
Short % of float—
Dividend yield4.81%
Beta (5Y)0.38
Valuation & profitability ratios
Trailing P/E9.14
Forward P/E—
PEG ratio4.31
Price / sales—
Price / book4.93
EV / revenue0.79
EV / EBITDA1.50
Gross margin81.99%
Operating margin42.54%
Profit margin35.35%
Return on equity59.81%
Return on assets18.73%
Debt / equity63.33
Current ratio0.87
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $309.06B | $290.40B | $232.26B | $176.95B | +6.4% |
| Operating revenue | $729.42B | $680.56B | $608.64B | $455.69B | +7.2% |
| Cost of revenue | $58.79B | $44.52B | $35.77B | $28.45B | +32.0% |
| Gross profit | $250.28B | $245.88B | $196.50B | $148.51B | +1.8% |
| Research & development | $52.04B | $48.06B | $32.44B | $24.05B | +8.3% |
| Selling, general & admin | $70.28B | $67.38B | $61.60B | $50.68B | +4.3% |
| Total operating expense | $122.62B | $117.54B | $93.92B | $73.70B | +4.3% |
| Operating income | $127.66B | $128.34B | $102.57B | $74.81B | -0.5% |
| Net interest income | -$3.18B | -$91.00M | $330.00M | -$320.00M | -3,393.4% |
| Pre-tax income | $130.54B | $127.19B | $104.67B | $69.06B | +2.6% |
| Tax provision | $28.11B | $26.20B | $20.99B | $13.54B | +7.3% |
| Net income | $102.43B | $100.99B | $83.68B | $55.52B | +1.4% |
| Net income to common | $102.43B | $100.99B | $83.68B | $55.52B | +1.4% |
| Basic EPS | 23.06 | 22.67 | 18.67 | 12.26 | +1.7% |
| Diluted EPS | 23.03 | 22.63 | 18.62 | 12.22 | +1.8% |
| EBIT | $134.75B | $128.83B | $105.22B | $69.44B | +4.6% |
| EBITDA | $149.41B | $137.38B | $114.63B | $76.80B | +8.8% |
| Basic shares | 4.44B | 4.45B | 4.48B | 4.53B | -0.3% |
| Diluted shares | 4.45B | 4.46B | 4.49B | 4.54B | -0.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $26.46B | $15.65B | $14.39B | $12.65B | +69.0% |
| Cash & short-term investments | $26.96B | $26.31B | $30.23B | $23.57B | +2.5% |
| Accounts receivable | $70.86B | $71.95B | $64.77B | $50.56B | -1.5% |
| Inventory | $49.62B | $40.85B | $31.81B | $24.39B | +21.5% |
| Total current assets | $172.45B | $161.79B | $139.65B | $108.19B | +6.6% |
| Property, plant & equipment | $208.38B | $161.68B | $90.96B | $66.67B | +28.9% |
| Goodwill & intangibles | $130.05B | $110.82B | $60.41B | $50.94B | +17.4% |
| Total assets | $542.90B | $465.63B | $314.49B | $241.26B | +16.6% |
| Total current liabilities | $215.66B | $217.61B | $169.66B | $120.94B | -0.9% |
| Current debt | $10.68B | $11.78B | $5.30B | $480.00M | -9.3% |
| Long-term debt | $111.70B | $84.25B | $15.98B | $20.77B | +32.6% |
| Total debt | $130.96B | $102.79B | $27.01B | $25.78B | +27.4% |
| Total liabilities | $348.86B | $322.14B | $207.93B | $157.77B | +8.3% |
| Retained earnings | $195.30B | $144.45B | $104.84B | $80.59B | +35.2% |
| Shareholder equity | $194.05B | $143.49B | $106.56B | $83.49B | +35.2% |
| Working capital | -$43.21B | -$55.83B | -$30.01B | -$12.75B | +22.6% |
| Net tangible assets | $63.99B | $32.66B | $46.16B | $32.55B | +95.9% |
| Shares issued | 4.46B | 4.46B | 4.51B | 4.56B | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $102.43B | $100.99B | $83.68B | $55.52B | — | +1.4% |
| Depreciation & amortisation | $14.67B | $8.54B | $9.41B | $7.36B | — | +71.6% |
| Stock-based compensation | — | $2.29B | $2.15B | $1.54B | $1.04B | — |
| Change in working capital | $3.74B | $2.59B | $19.71B | -$5.54B | — | +44.3% |
| Operating cash flow | $119.10B | $120.97B | $108.91B | $78.89B | — | -1.5% |
| Capital expenditure | -$90.11B | -$51.31B | -$38.90B | -$14.75B | — | -75.6% |
| Investing cash flow | -$79.16B | -$128.90B | -$43.89B | -$24.92B | — | +38.6% |
| Share buybacks | -$1.39B | -$20.18B | -$29.92B | -$24.09B | — | +93.1% |
| Dividends paid | -$51.76B | -$44.14B | -$31.77B | -$25.30B | — | -17.3% |
| Financing cash flow | -$28.41B | $8.73B | -$63.16B | -$51.80B | — | -425.2% |
| Free cash flow | $28.99B | $69.66B | $70.01B | $64.13B | — | -58.4% |
| End cash position | $26.46B | $15.65B | $14.39B | $12.65B | — | +69.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $78.49B | $96.82B | $79.14B | $74.98B | $76.86B | — | -18.9% |
| Operating revenue | $78.49B | $96.82B | $79.14B | $74.98B | $76.86B | — | -18.9% |
| Cost of revenue | $17.10B | $13.60B | $15.15B | $17.90B | $12.85B | — | +25.8% |
| Gross profit | $61.39B | $83.22B | $64.00B | $57.07B | $64.01B | — | -26.2% |
| Research & development | $17.79B | $10.28B | $14.65B | $15.39B | $11.69B | — | +73.0% |
| Selling, general & admin | $16.31B | $13.22B | $17.44B | $17.88B | $18.85B | — | +23.4% |
| Total operating expense | $34.33B | $23.61B | $32.26B | $33.39B | $30.56B | — | +45.4% |
| Operating income | $27.06B | $59.62B | $31.74B | $23.68B | $33.45B | — | -54.6% |
| Net interest income | -$186.00M | $2.55B | $2.45B | $1.83B | $356.00M | — | -107.3% |
| Pre-tax income | $26.88B | $62.17B | $34.19B | $25.52B | $33.80B | — | -56.8% |
| Tax provision | $5.89B | $13.62B | $7.29B | $5.51B | $7.30B | — | -56.8% |
| Net income | $20.99B | $48.56B | $26.89B | $20.01B | $26.50B | — | -56.8% |
| Net income to common | $20.99B | $48.56B | $26.89B | $20.01B | $26.50B | — | -56.8% |
| Basic EPS | 4.74 | 10.93 | 6.06 | — | 5.96 | 6.54 | -56.6% |
| Diluted EPS | 4.74 | 10.91 | 6.04 | — | 5.96 | 6.53 | -56.6% |
| EBIT | $28.38B | $65.67B | $31.74B | $23.68B | $38.76B | — | -56.8% |
| EBITDA | $28.38B | $69.21B | $31.74B | $31.44B | $43.60B | — | -59.0% |
| Basic shares | 4.43B | 4.44B | 4.44B | — | 4.45B | 4.44B | -0.3% |
| Diluted shares | 4.44B | 4.45B | 4.45B | — | 4.45B | 4.45B | -0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $44.48B | $21.13B | $26.46B | $32.08B | $18.43B | +110.5% |
| Cash & short-term investments | $44.98B | $21.63B | $26.96B | $32.58B | $18.93B | +108.0% |
| Accounts receivable | $88.95B | $82.56B | $70.86B | $75.42B | $69.58B | +7.7% |
| Inventory | $51.35B | $51.35B | $49.62B | $47.50B | $45.65B | 0.0% |
| Total current assets | $208.70B | $177.32B | $172.45B | $181.88B | $162.71B | +17.7% |
| Property, plant & equipment | $231.76B | $219.97B | $208.38B | $193.24B | $180.76B | +5.4% |
| Goodwill & intangibles | $122.06B | $129.91B | $130.05B | $106.59B | $107.87B | -6.0% |
| Total assets | $594.94B | $559.22B | $542.90B | $512.29B | $482.15B | +6.4% |
| Total current liabilities | $239.08B | $225.16B | $215.66B | $234.36B | $207.52B | +6.2% |
| Current debt | $18.33B | $27.21B | $10.68B | $12.03B | $11.96B | -32.6% |
| Long-term debt | $121.79B | $119.17B | $111.70B | $89.18B | $87.31B | +2.2% |
| Total debt | $140.13B | $146.38B | $130.96B | $101.21B | $99.27B | -4.3% |
| Total liabilities | $373.66B | $356.16B | $348.86B | $342.39B | $314.09B | +4.9% |
| Retained earnings | $224.16B | $206.42B | $195.30B | $168.53B | $164.45B | +8.6% |
| Shareholder equity | $221.28B | $203.06B | $194.05B | $169.90B | $168.07B | +9.0% |
| Working capital | -$30.39B | -$47.84B | -$43.21B | -$52.48B | -$44.82B | +36.5% |
| Net tangible assets | $99.22B | $73.16B | $63.99B | $63.31B | $60.20B | +35.6% |
| Shares issued | 4.46B | 4.46B | 4.46B | 4.44B | 4.44B | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $20.99B | $48.56B | $26.89B | $20.01B | $26.50B | -56.8% |
| Depreciation & amortisation | $10.30B | $3.54B | -$1.75B | $7.76B | $4.83B | +191.4% |
| Change in working capital | $13.32B | -$33.23B | $20.37B | -$9.16B | $7.94B | +140.1% |
| Operating cash flow | $55.20B | $24.08B | $7.62B | $44.98B | $41.77B | +129.2% |
| Capital expenditure | -$12.80B | -$12.04B | -$43.84B | -$15.41B | -$16.27B | -6.3% |
| Investing cash flow | -$12.76B | -$11.71B | -$42.81B | -$16.25B | -$14.12B | -9.0% |
| Share buybacks | -$3.50B | -$2.40B | $0 | $0 | $0 | -45.8% |
| Dividends paid | $0 | -$35.31B | $0 | -$16.66B | $174.00M | +100.0% |
| Financing cash flow | -$19.13B | -$17.43B | $29.47B | -$15.14B | -$47.35B | -9.7% |
| Free cash flow | $42.40B | $12.04B | -$36.22B | $29.56B | $25.50B | +252.0% |
| End cash position | $44.48B | $21.13B | $26.46B | $32.08B | $18.43B | +110.5% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $73.15B | -2.4% |
| Next quarter | — | — | $75.24B | -4.9% |
| Current year | — | — | $300.49B | -2.8% |
| Next year | — | — | $304.51B | +1.3% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders5.27%
Held by institutions33.78%
Institutions holding1.09K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
37.93
-1.42% from price
SMA 20
40.13
-6.83% from price
SMA 50
43.91
-14.84% from price
SMA 100
45.10
-17.09% from price
SMA 200
45.33
-17.52% from price
EMA 12
38.61
-3.15% from price
EMA 26
40.71
-8.14% from price
EMA 50
42.67
-12.37% from price
RSI (14)
26.7
Oversold
MACD (12,26,9)
-2.10
Hist -0.12
ATR (14)
1.73
4.61% of price
Realised vol 30D
29.9%
Annualised
Bollinger upper
45.15
20, 2σ
Bollinger lower
35.11
20, 2σ
50 / 200 cross
Death
43.91 vs 45.33
Trend bias
Below 200
-17.52%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.61
Less volatile than market
Correlation to SPY
0.17
Largely independent
Realised vol 30D
29.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-44.6%
Peak to trough
Max drawdown 5Y
-76.5%
Peak to trough
ATR 14
1.73
4.61% of price
Beta (reported)
0.38
5Y monthly, from filing
Dividends & splits
Forward rate$1.80 / yr
Forward yield4.81%
5-year avg yield1.49%
Payout ratio44.66%
Ex-dividend dateAug 14, 2026
Next pay dateAug 20, 2019
Last split2:1
Split dateSep 13, 2023
Headlines
Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?
Motley Fool · 12h ago
Prediction: LLY Has Another Massive Growth Opportunity Beyond Weight Loss
24/7 Wall St. · 20h ago
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
MT Newswires · 22h ago
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know
Zacks · 23h ago
Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?
Motley Fool · 23h ago
VKTX Down 16% in a Month: Time to Invest or Exit the Stock?
Zacks · 1d ago
Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?
Zacks · 1d ago
Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026–2036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight
GlobeNewswire · 2d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.